Proportion public drug program spending Canada by therapy 2022

This statistic shows the proportion of the total public drug program expenditures in Canada by broad therapeutic category in 2022. In that year, over 23 percent of total drug program spending was dedicated to antineoplastic and immunomodulating agents.

Distribution of total public drug program spending in Canada by therapy in 2022

Characteristic	Share of total public drug spending
Antineoplastic and immunomodulating agents	23.3%
Alimentary tract and metabolism	15.6%
Nervous system	14.5%
Cardiovascular system	8.9%
Respiratory system	7.3%
Sensory organs	6.4%
Blood and blood-forming organs	5.4%
Anti-infectives for systemic use	4.6%
Musculoskeletal system	2.8%
Genitourinary system and sex hormones	1.9%
Systemic hormonal preparations (excl. sex hormones and insulins)	1.5%
Dermatologicals	0.9%
Anti-parasitic products, insecticides and repellents	0.1%
Various	0.8%
Unassigned*	1.5%
Non-drug products**	4.4%

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

November 2023

More information

Region

Canada

Survey time period

2022

Supplementary notes

Currently, the Northwest Territories and Nunavut do not submit data to NPDUIS.
* This category includes products without an assigned Anatomical Therapeutic Chemical (ATC) code.
** Non-drug products include, but are not limited to, diabetic supplies, wound care, ostomy supplies and pharmaceutical services.

Citation formats